Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

T cells and B cells join to fight solid tumors, Winship study finds

T helper 17 cells and B cells can work in concert to spark long-lasting protection against solid tumors, a research team at Winship Cancer Institute of Emory University found.

August 01, 2025

Vol.51 No.30

Clinical Roundup

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

In Brief

Jill Barnholtz-Sloan joins Emory Winship as chief administrative officer

Jill S. Barnholtz-Sloan was appointed chief administrative officer and associate director for research administration at Winship Cancer Institute of Emory University, effective July 21.

July 18, 2025

Vol.51 No.28

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

In Brief

Neil Iyengar joins Winship as survivorship director, co-director of Breast Oncology Program

Breast medical oncologist and cancer survivorship expert Neil M. Iyengar was appointed director of survivorship services at Winship Cancer Institute of Emory University.

July 03, 2025

Vol.51 No.26

Clinical Trials & Tribulations

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals. But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half. Simply stated, cost is the product of (price per unit times the number of units purchased).

June 20, 2025

Vol.51 No.24

By Mark J. Ratain, David A. Hyman, Jill E. Feldman, Beth R. Jacobson and Allen S. Lichter

Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC

YOU MAY BE INTERESTED IN

T cells and B cells join to fight solid tumors, Winship study finds

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Jill Barnholtz-Sloan joins Emory Winship as chief administrative officer

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Neil Iyengar joins Winship as survivorship director, co-director of Breast Oncology Program

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

Renew today!

Subscriber content

Never miss an issue!

Login